HMG-CoA reductase inhibitors (statins) have led to remarkable protection from cardiovascular (CV) morbidity and mortality in patients with CV disease or CV risk factors. However, despite the high burden of CV disease in patients with ESRD, studies have not demonstrated the same benefit in this patient population.
Dr. Ardhanari is affiliated with the Division of Cardiovascular Medicine at University of Missouri – Columbia School of Medicine in Ciolumbia, MO. Dr. Whaley-Connell is a nephrologist affiliated with the Harry S. Truman Memorial VA Medical [read more...]
See the Current Standings! | For more on NephMadness 2015 | #NephMadness or #HeartRegion on Twitter The hype around this bracket is electrifying baby! The prospect of being freed from our “diuretic prison” enticing! There were no sweeps, [read more...]
Submit your picks! | For more on NephMadness 2015 | #NephMadness or #HeartRegion on Twitter This region is like the Showtime Lakers of the 80s. Cardiology always packs the house by combining crowd pleasers like acute illness, therapeutic advances, [read more...]